Department of Pharmacology, Biomedical Sciences Institute, University of São Paulo, São Paulo 05508-000, Brazil.
BMB Rep. 2020 Aug;53(8):413-418. doi: 10.5483/BMBRep.2020.53.8.087.
ANKHD1 (ankyrin repeat and KH domain containing 1) is a large protein characterized by the presence of multiple ankyrin repeats and a K-homology domain. Ankyrin repeat domains consist of widely existing protein motifs in nature, they mediate protein-protein interactions and regulate fundamental biological processes, while the KH domain binds to RNA or ssDNA and is associated with transcriptional and translational regulation. In recent years, studies containing relevant information on ANKHD1 in cancer biology and its clinical relevance, as well as the increasing complexity of signaling networks in which this protein acts, have been reported. Among the signaling pathways of interest in oncology regulated by ANKHD1 are Hippo signaling, JAK/STAT, and STMN1. The scope of the present review is to survey the current knowledge and highlight future perspectives for ANKHD1 in the malignant phenotype of cancer cells, exploring biological, functional, and clinical reports of this protein in cancer. [BMB Reports 2020; 53(8): 413-418].
ANKHD1(锚蛋白重复和 KH 结构域包含 1)是一种具有多个锚蛋白重复和 K 同源结构域的大型蛋白。锚蛋白重复结构域由自然界中广泛存在的蛋白基序组成,它们介导蛋白-蛋白相互作用,并调节基本的生物过程,而 KH 结构域与 RNA 或 ssDNA 结合,并与转录和翻译调节有关。近年来,已有研究报道了 ANKHD1 在癌症生物学及其临床相关性中的相关信息,以及该蛋白作用的信号网络的日益复杂化。在受 ANKHD1 调节的肿瘤学中感兴趣的信号通路中,有 Hippo 信号通路、JAK/STAT 和 STMN1。本综述的范围是调查当前的知识,并强调 ANKHD1 在癌细胞恶性表型中的未来展望,探讨该蛋白在癌症中的生物学、功能和临床报告。[BMB 报告 2020;53(8): 413-418]。